Puma Biotechnology Q1 net loss of $3.8 million; raises 2026 revenue guidance
Puma Biotechnology reported first quarter 2026 results, with total revenue of $44.8 million, down from $46.0 million a year earlier, and a GAAP net loss of $3.8 million, compared with net income of $3.0 million in the first quarter of 2025. The company raised its full-year 2026 total revenue and net income outlook, and said it repaid its remaining debt on May 4, 2026.
Key points
- Total revenue was $44.8 million versus $46.0 million in Q1 2025; net product revenue was $42.0 million versus $43.1 million.
- GAAP net loss of $3.8 million, or $0.07 per share, versus net income of $3.0 million, or $0.06 per share, a year earlier.
- Full-year 2026 total revenue outlook raised to $222–$229 million from $214–$221 million; net income outlook raised to $16–$19 million from $10–$13 million.
- Final payment under the 2021 Note Purchase Agreement was remitted on May 4, 2026, reducing outstanding debt to zero.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.